Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Q2 FY23 Earnings Presentation
25 slides from Valiant Organics's earnings presentation, Nov 9, 2022
Slide 1: Valiant Organics Limited
•••• Valiant Organics Limited November 09, 2022 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD. National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, "Exchange Plaza "Plot No .C/1, Mumbai - 400 001. G Block Sandra -Kurla Complex, Sandra (E), M
Slide 2: Earnings Presentation | Q2/H1-FY23
Earnings Presentation | Q2/H1-FY23
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 5: Chemistries And Product Basket
Chemistries And Product Basket H1-FY23 Revenue Share Hydrogenation Ammonolysis 45% Key Products: Industries Served: Key Products: • Ortho Anisidine • Dyes Industries Served: • Para Anisidine • Pigments • Para Nitro Aniline • Dyes • Ortho Chloro Para Nitro Aniline • IPPCA • Pharmaceutical • Pigments
Slide 6: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 27,000 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 7: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 8: Capex Projects
Capex Projects Installed Capacity Approx. Capex Product Project Status Remarks (MT per month) (INR Mn) Commissioned Para Nitro Aniline (PNA) & Completing phase-wise • Expansion from 550 TPM to 750 TPM at Vapi plant Ortho Chloro Para Nitro 550 ~ 70 • Full capacity addition in progress Aniline (OCPNA)
Slide 9: Q2/H1-FY23 Highlights
Q2/H1-FY23 HIGHLIGHTS Valiant Organics Limited |November 2022 8
Slide 10: Consolidated Financial Highlights
CONSOLIDATED FINANCIAL HIGHLIGHTS Q2-FY23 Consolidated Financial Highlights H1-FY23 Consolidated Financial Highlights INR 2,641 Mn INR 5,300 Mn Operational Revenue Operational Revenue INR 419 Mn INR 737 Mn Operating EBITDA Operating EBITDA 15.87% 13.91% Operating EBITDA Margin Operating EBITDA Margi
Slide 11: Q2/H1-FY23 Operational Highlights
Q2/H1-FY23 Operational Highlights Q2-FY23 Revenue Break-up – Chemistries Others, 6% • Q2-FY23 closed on a positive note. Although the revenue de-grew marginally, Chlorination, profitability improved over the previous quarter. Revenue degrowth was 17% primarily due to decline in Chlorination revenues
Slide 12: Sales Volumes and Revenues by Key Chemistries
Key Chemistries Chlorination Hydrogenation Ammonolysis Others REVENUES (INR Mn) 1,104 1,106 770 1, 200 775 250 800 686 1, 000 770 199 163 700 765 200 600 800 760 155 500 412 411 600 560 755 749 150 750 740 400 745 100 400 300 740 200 735 50 200 100 730 725 0 0 0 Q2-FY22 Q1-FY23 Q2-FY23 Q2-FY22 Q1-FY
Slide 13: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance Particulars (INR Mn) Q2-FY23 Q2-FY22 Y-o-Y Q1-FY23 Q-o-Q Revenue from Operations 2,641 2,732 (3.3)% 2,660 (0.7)% Total Expenses 2,222 2,259 (1.6)% 2,341 (5.1)% EBITDA 419 473 (11.4)% 319 31.3% EBITDA Margins (%) 15.87% 17.31% (144) Bps 11.99% 388 Bps Othe
Slide 14: YTD Consolidated Financial Performance
YTD Consolidated Financial Performance Particulars (INR Mn) H1-FY23 H1-FY22 Y-o-Y Revenue from Operations 5,300 5,172 2.5% Total Expenses 4,563 4,196 8.7% EBITDA 737 976 (24.5)% EBITDA Margins (%) 13.91% 18.87% (496) Bps Other Income 38 26 46.2% Depreciation 139 135 3.0% Finance Cost 52 34 52.9% PBT
Slide 15: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance Particulars (INR Mn) Q2-FY23 Q2-FY22 Y-o-Y Q1-FY23 Q-o-Q Revenue from Operations 2,323 2,127 9.2% 2,346 (1.0)% Total Expenses 2,009 1,760 14.1% 2,084 (3.6)% EBITDA 314 367 (14.4)% 262 19.8% EBITDA Margins (%) 13.52% 17.25% (373) Bps 11.17% 235 Bps Other Inc
Slide 16: YTD Standalone Financial Performance
YTD Standalone Financial Performance Particulars (INR Mn) H1-FY23 H1-FY22 Y-o-Y Revenue from Operations 4,669 3,970 17.6% Total Expenses 4,094 3,210 27.5% EBITDA 575 760 (24.3)% EBITDA Margins (%) 12.32% 19.14% (682) Bps Other Income 16 30 (46.7)% Depreciation 132 124 6.5% Finance Cost 50 33 51.5% P
Slide 17: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW Valiant Organics Limited |November 2022 16
Slide 18: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY20 FY21* FY22* H1-FY23* Operational Income 6,749 7,548 11,533 5,300 Total Expenses 4,946 5,496 9,484 4,563 EBITDA 1,803 2,052 2,049 737 EBITDA Margins (%) 26.71% 27.19% 17.77% 13.91% Other Income 63 59 74 38 Depreciation 158 212 296 139
Slide 19: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (INR Mn) FY21* FY22* H1-FY23* Particulars (INR Mn) FY21* FY22* H1-FY23* EQUITY 5,086 6,489 6,816 Non-Current Assets 5,731 6,652 7,000 a) Equity Share Capital 272 272 272 a) Property, Plant and Equipment 4,967 5,303 5,375 b) Other Equity 4,747 5,856 6,121 b) Cap
Slide 20: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY20 FY21* FY22* H1-FY23* Revenue from Operations 5,836 5,742 9,484 4,669 Total Expenses 4,103 4,170 7,834 4,094 EBITDA 1,733 1,572 1,650 575 EBITDA Margins (%) 29.69% 27.38% 17.40% 12.32% Other Income 52 169 56 16 Depreciation 130 186 273
Slide 21: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY21* FY22* H1-FY23* Particulars (INR Mn) FY21* FY22* H1-FY23* EQUITY 5,023 6,031 6,240 Non-Current Assets 5,798 6,787 7,094 a) Equity Share Capital 272 272 272 a) Property, Plant and Equipment 4,771 5,085 5,143 b) Other Equity 4,747 5,755 5,964 b) Capit
Slide 22: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 80.00% 1,282 1,309 1,279 2,052 14, 000 1, 400 2,049 11,533 2,100 12, 000 1,803 70.00% 1,800 1, 100 10, 000 60.00% 1,500 50.00% 7,548 800 6,749 8, 000 1,200 40.00% 5,300
Slide 23: Capital Market Information
Capital Market Information 30% Share Price up to 30th September, 2022 20% 10% 0% -10% -20% -30% -40% -50% -60% -70% Oct/21 Nov/21 Dec/21 Jan/22 Feb/22 Mar/22 Apr/22 May/22 Jun/22 Jul/22 Aug/22 Sep/22 Valiant Sensex Price Data (As on 30th September, 2022) INR Shareholding pattern (As on 30th Septembe
Slide 24: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 25: Thank You
THANK YOU Valiant Organics Limited |November 2022 24